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Drug susceptibility testing (DST) of Mycobacterium tuberculosis is a crucial procedure to
determine the effective drug regimen for patients’ treatment. Reporting of erroneous
DST results to the treating physician has adulterous effects on patients. As a first study
of its type, the inconsistencies in reporting DST results of rifampicin and isoniazid from
Saudi Arabia were assessed. An automated liquid culture-based DST and a molecular muta-
tion detection technique were used. Performance of first-line drug susceptibility testing of
1904 clinical isolates showed 44 inconsistent results. The majority of the cases reported as
MDR-TB from the referral laboratories could not reproduce the same results at a different
site (Mycobacteriology Research Section). Of the 44 cases, 16 (36.3%) showed false resis-
tance to isoniazid and rifampicin and on the other hand, 14 (31.8%) cases showed false sus-
ceptibility to the same drugs. The possible causes for the inconsistencies and
recommendations to overcome the biases based on this experience are discussed.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Tuberculosis (TB) is one of the most ancient diseases of man-
kind caused by Mycobacterium tuberculosis [1]. Despite the exis-
tence of drugs and vaccines for the last six decades, still TB
continues to be a major threat worldwide with high morbidity
and mortality. The most substantial reason for this phenom-
enon is the emergence of drug resistant strains, particularly
the multidrug resistance (resistance to isoniazid and rifampi-
cin). Multidrug-resistant TB (MDR-TB) has become a serious
threat to global TB control as a result of the difficulties in
diagnosis, treatment and associated high cost to TB control
programs. The emergence of extensively drug-resistant TB
(XDR-TB), with its poor treatment outcome and the extraordi-
nary potential of high mortality in HIV-infected patients and
rapid transmission, has been alarmed public health officials.
MDR-TB does not respond to treatment with first-line drugs,-African Society for Myco
2; fax: +966 1 4627858.
u.sa (B. Varghese), Rujakaand its management using second-line drugs has not yet been
properly organized by most TB control programs [2,3]. Recent
findings of the World Health Organization showed globally
the rate of any drug resistance is 20% and multidrug resis-
tance is 5.3% of the total notified TB cases [4].
TB drug susceptibility testing (DST) has been documented
to be one of the most complex procedures to perform in the
mycobacteriology laboratory; it requires technical expertise
to produce valid and reliable results, and it requires 4–6 weeks
to get the final results. Valid and reliable DST is important to
design appropriate drug regimens. Since the clinical decisions
are made based on the laboratory findings, the reliability of
results and the potential of the laboratory to test the drug sus-
ceptibility are imperative.
Saudi Arabia is a moderate TB burden country with an
established national tuberculosis control program (NTP). The
National Tuberculosis Program (NTP) of the country createdbacteriology. All rights reserved.
_12@hotmail.com (R. Al-Omari), hajoj@kfshrc.edu.sa (S. Al-Hajoj).
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ries to confirm the diagnosis and perform drug susceptibility
testing. All the laboratories are following the WHO guidelines
and using the same technology (MGIT 960, Becton Dickinson,
Maryland, USA) for mycobacterial culture and DST. A recent re-
port from WHO showed that the new case rate is 24/100,000
population with a 2.1% of MDR-TB cases. However, the drug
resistant rates in Saudi Arabia were found to be fluctuating
from 2–44% [5–7]. Recently while conducting a nationwide drug
surveillance survey, a considerable inconsistency on reporting
DST results was observed. This study focused on the two most
important drugs isoniazid and rifampicin as they are the key
drugs for primary TB treatment and predictors for MDR-TB
confirmation. The inconsistencies found in the reports led to
the design of this study to compare the DST results using the
same culture technique and a rapid molecular assay. This
study attempts to explain the possibilities of misclassification
of MDR-TB, which holds very high clinical implications. Possi-
ble reasons for such inconsistencies and recommendations to
overcome the biases are discussed.Materials and Methods
Study samples
A nationwide survey of drug-resistant tuberculosis obtained
2235 non-repetitive mycobacterial clinical isolates from nine
regional laboratories during the period 2009–2010. Of the total,
256 (11.4%) were found to be non tuberculous Mycobacteria
(NTM) and 75 (3.4%) isolates were lost because of contamina-
tion. The remaining 1904 isolates were subjected to first-line
DST. When the primary data were analyzed, 44 inconsistent
results were observed and enrolled into the study.
Drug Susceptibility Testing
All the isolates enrolled in the study were subjected to first-
line DST by using the commercially available kit BACTEC
MGIT SIRE (Becton Dickinson, Maryland, USA) as per the rec-
ommendation of the manufacturer. The concentrations of the
drugs used were 0.1 lg/ml for INH and 1 lg/ml for RIF. Isolates
with inconsistent results were subjected to DST twice at dif-
ferent intervals to reproduce similar results in the mycobacte-
rial research section of King Faisal Hospital and Research
Centre [MRS-KFSHRC]. Moreover, the kits used each time be-
long to different lots and batches.
Quality Assurance
At MRS-KFSHRC strict and regular practices of internal and
External Quality Assurance (EQA) were followed. In brief, bi-
monthly internal quality assurance testing was carried out
for the MGIT SIRE (streptomycin, isoniazid, rifampicin, and
ethambutol) kit with the standard strain of M. tuberculosis
(ATCC 27294). In addition, the center regularly participates in
the EQA surveys conducted by the College of American Pathol-
ogists (Illinois, USA). Furthermore, the section participates in
DST EQA analysis coordinated by the World Health Organiza-
tion (Supranational Reference Laboratory, Cairo, Egypt).Detection of mutations conferring resistance to rifampicin and
isoniazid
Genomic DNA was extracted by using the standard spin col-
umn technique (QIAAmp DNA Mini kit, QIAGEN, GmbH, Ger-
many) as per the manufacturer’s protocol. All the isolates
were genotyped to determine the mutations conferring INH
or RIF resistance by using the PCR-based reverse blot hybrid-
ization assay, Genotype MTBDR Plus (Hain Lifescience,
Nehren, Germany) according to the manufacturer’s recom-
mendations. In brief, a PCR was conducted by using the prim-
ers provided by the manufacturer, and reverse blot
hybridization based on strips was carried out by using the
automated system GT Blot 48 (Hain Life Science, Nehren,
Germany). The strips after hybridization were scanned by
using the automated system Geno-Scan (Hain Life Science,
Nehren, Germany). The results were interpreted by using
the software Blotrix (Hain Life Science, Nehren, Germany).
Isolates with mutations in the rpoB gene and katG/inhA were
considered to be RIF and INH resistant respectively. Strains
possessing mutations in both rpoB and katG/inhA genes were
regarded as MDR-TB.
Data analysis
The statistical analysis of the results of susceptibility testing
and genotyping were carried out by using the software Epi-
info V6.0 (CDC, Atlanta, USA).
Results
Out of 1904 isolates, 44 (2.3%) isolates showed discrepant sus-
ceptibility results obtained from referral laboratories for
either INH or RIF or both when tested at MRS-KFSHRC. Of
the 44 isolates, 25 of them were reported as MDR-TB, 14 as
susceptible to both drugs, and 5 of them resistant to INH by
the regional laboratories. On the other hand, DST results at
MRS-KFSHRC showed 19 as MDR-TB, 17 as susceptible to both
drugs, 6 as INH resistant and 2 RIF resistant, respectively.
Molecular genotyping results showed 19 as MDR-TB, 5 as
INH resistant and 2 as RIF resistant, respectively. The remain-
ing 18 isolates were observed as susceptible to both drugs;
one phenotypically INH-resistant isolate showed susceptibil-
ity by the mutation detection assay (Table 1). Surprisingly,
from the referral laboratories, 38.6% of the pan susceptible
isolates were classified as MDR-TB, and on the other hand,
31.8% of isolates were misclassified vice versa.
Discussion
The goal of this study was to evaluate the inconsistencies on
reporting rifampicin and isoniazid susceptibility at the regio-
nal TB laboratories emphasizing on the misidentification of
MDR-TB. An attempt was made to formulate the current prob-
lems that may be faced by TB diagnostic facilities anywhere
in the world. The limitations of current practices and recom-
mendations to improve the performances were discussed.
Drug susceptibility testing in mycobacteriology needs sig-
nificant technical proficiency to produce reliable and accurate
Table 1 – Phenotypic and genotypic drug susceptibility patterns of the 44 study samples.
Drug susceptibility results Molecular typing Total cases
Site-1a Site-2Ab Site-2Bc N = 44
INH RIF INH RIF INH RIF INH RIF
Rd R R Se R R R R 1 (2.3%)
R S R S R S S S 1 (2.3%)
R R R S R S R S 5 (11.4%)
R R S S S S S S 17 (38.6%)
S S R R R R R R 14 (31.8%)
R R S R S R S R 2 (4.5%)
R S R R R R R R 4 (9.1%)
A variation on the results of isoniazid and rifampicin susceptibility from three different phenotypic testing and a molecular method is detailed.
The reproducibility of the results is checked in duplicate runs at the research section.
a Regional Laboratories.
b Mycobacteriology research section Result-1.
c Mycobacteriology research section Result-2.
d Resistant.
e Sensitive.
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ratories discrepant results can occur for many reasons. A cer-
tain proportion of drug-resistant bacteria exists in all
populations of drug-susceptible M. tuberculosis. In addition,
current methods for susceptibility testing of M. tuberculosis
complex (MTBC) are based on proportion methods, which rely
on a bacteriological definition of drug resistance that was
developed in recognition of the difficulties in defining clinical
resistance for mycobacteria. These methods provide qualita-
tive results of ‘‘susceptible’’ or ‘‘resistant,’’ defining resistance
as growth of greater than 1% of an inoculum of bacterial cells
in the presence of a ‘‘critical’’ concentration of the drug. The
critical concentrations of drugs were established on an em-
piric basis and adopted by international convention. The crit-
ical concentration represents the lowest concentration of
drug that inhibit 95% of ‘‘wild strains’’ of M. tuberculosis and
not inhibiting strains of M. tuberculosis isolated from patients
unresponsive to therapy and considered resistant. The other
key factors which may influence the inter-lab and intra-lab
results are: bacterial population (repeated sub-culturing may
lead to losing the slow-growing resistant population and false
susceptible result), different growth kinetics, cross-contami-
nation, growth difficulties of some strains, and minimum
inhibitory concentration (MIC) of some isolates which is clo-
ser to the critical concentration [8,9].
In this study, the drug susceptibility results of the regional
referral laboratories were compared with the MRS-KFSHRC
results. Molecular assay to determine the mutations responsi-
ble for drug resistance was performed for a reconfirmation of
results. However, low-grade discrepancies (2.3%) were found
among MRS-KFSHRC rsults, even on defining MDR-TB. Of
the total (44 cases), 24 (54.5%) cases were reported as MDR-
TB from the regional laboratories which could not reproduce
the same results at MRS-KFSHRC. On the other hand, 14
(31.8%) cases reported as susceptible TB by the regional labo-
ratories showed up as MDR-TB results in molecular testing as
well as DST at MRS-KFSHRC. Both events of misclassification
of MDR-TB have serious clinical implications; either the pa-
tient receive a highly complex wrong drug regimen or donot receive an adequate therapy. In addition, one phenotypi-
cally INH resistant isolate showed no mutation in the geno-
typic assay, which could possibly be due to an uncommon
mutation in a gene other than katG or inhA as it was found
in a low level in some isolates previously [10].
Interestingly a new phenomenon of TB transmission is
also underway in the country as per the recent study
(Varghese B. et al., Publication In Press) which showed that
there is an endogenous reactivation of TB infection followed
by an exogenous reinfection caused by ongoing drug-resistant
strain transmission, mainly among African migrants.
However, migrants from Asia and Saudi nationals also pos-
sess a low-level risk of this new phenomenon. In addition
concurrent infection by multiple strains was also noticed.
This could present two different DST results at the same time
or within a short interval depending on the drug susceptibility
profile of concurrently infected strains, particularly if the
patient received a drug-resistant strain recently.
Nevertheless, these phenomena could also be contributing
factors in inconsistent results of DST as described previously
[11,12].
Conclusion and Recommendations
The crucial TB-DST particularly defining MDR-TB in periphe-
ral diagnostic laboratories of Saudi Arabia has a noticeable le-
vel (35.9%) of inconsistencies. The obtained results from the
referral laboratories showed discrepancies which have seri-
ous consequences on patient management. An urgent reeval-
uation and training are needed for the staff involved in the
TB-DST. Even though the discrepancies are common in low
grade around the globe, false reporting of MDR-TB cases has
serious clinical implications. Rapid molecular testing can be
preferred for screening suspected high risk groups for drug
resistance. High level, inconsistent results propose an imme-
diate action to standardize the guidelines and reevaluate the
existing policies.
It is recommended that the following practices be imple-
mented to improve and to make highly reproducible results
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experiences [8]:
(1) Existing quality control programs need immediate
enhancement. Strict practice of internal quality assur-
ance must be practiced in all the regional laboratories.
This would include testing of kits and media used with
standard strains (ATCC-American Type Culture collec-
tion, VA, USA) and strict adherence to standard operat-
ing protocols.
(2) An intra-laboratory quality assurance program must be
run between the laboratories that are involved in
performing DST in a frequency of at least twice in a
year. A central laboratory must coordinate with the
sampling, result analysis and grading of the participat-
ing laboratories with proper auditable documentations.
(3) Participation in international EQA programs should be
implemented at all regional laboratories. To date, the
most trusted international proficiency testing programs
for TB-DST available are CAP-E Survey (College of Amer-
ican Pathologists, Illinois, USA), and MTB-DST profi-
ciency testing (WHO/IUATLD, Supranational Reference
Laboratory; Center for Disease Control, Atlanta, GA,
USA and American Proficiency Institute, Traverse City,
MI, USA).
(4) Training and education of the staff in the laboratories
which perform DST; and clinicians interpreting the test
results should be available on a recurring basis.
(5) A clinical database of all the reported patients must be
created and used as a reference for studying compli-
cated cases.
(6) Indeed, considering molecular testing as an alternative
for confirming drug susceptibility results or as a screen-
ing for MDR-TB or XDR-TB is new, therefore it needs to
be standardized and adapted to practice in all the refer-
ral laboratories. There are commercially available kits
for first-line and second-line drug resistance screening
based on mutation detection from different
manufacturers.
(7) Tuberculosis research in Saudi Arabia or any developing
country should be focused on the following: adaptabil-
ity (cost and capability) of rapid molecular methods for
the screening of drug resistance in high-risk groups, the
role of molecular methods to detect primary resistance
and in treatment failures; assessment of current prac-
tices in the laboratories and referral strategies to
develop optimal strategies to improve TB detection
and DST turnaround times; and clinical utility of MIC
testing.
(8) A central reference laboratory with all the sophisticated
technologies should be designated to be involved inhandling all complicated cases and coordinating with
all the intra-lab quality control assessments.Acknowledgements
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